Sana Biotechnology and Mayo Clinic announce collaboration to advance SC451 for type 1 diabetes

Sana Biotechnology and Mayo Clinic announced a strategic collaboration to advance development and delivery of SC451, an investigational cell therapy for type 1 diabetes, and Mayo Clinic will make an equity investment in Sana.

Sana Biotechnology and Mayo Clinic announced a strategic collaboration to advance SC451, an investigational cell replacement therapy for type 1 diabetes. The partnership will focus on developing, validating, and standardizing protocols and processes for handling and delivering SC451 across clinical settings. Mayo Clinic will also work to advance its capabilities in delivering investigational islet cell therapies. The collaboration includes an equity investment by Mayo Clinic in Sana. Key facts: - The collaboration is intended to accelerate development and access to potentially curative therapies for patients with type 1 diabetes, centered on Sana's investigational candidate SC451. - Mayo Clinic will help develop, validate, and standardize protocols and processes to support safe, scalable, and consistent delivery of SC451 at Mayo sites and other clinical locations. - In connection with the agreement, Mayo Clinic will make an equity investment in Sana and has an option to make an additional investment under the terms of the agreement. - SC451 is described as an investigational, gene-modified, stem cell-derived pancreatic islet cell therapy that uses Sana's hypoimmune technology to address allogeneic and autoimmune rejection. - The article reports that an investigator-sponsored study of donor-derived, HIP-modified pancreatic islets showed these cells survived, evaded immune detection, and produced insulin through 14 months of follow-up. - Sana expects to file an Investigational New Drug (IND) application and to initiate a Phase 1 clinical study of SC451 as early as this year. Summary: The collaboration brings Mayo Clinic's multidisciplinary expertise in transplant medicine and immunology to support development and clinical delivery processes for SC451 and includes a Mayo equity investment. The companies report plans to pursue regulatory filings and to initiate a Phase 1 study as early as this year. The timing and outcomes of those regulatory and clinical steps remain subject to review and other uncertainties.